Auron Therapeutics Inc. has received FDA clearance of its IND application for its oral KAT2A/B degrader AUTX-703 in hematological malignancies. A phase I proof-of-concept trial in acute myeloid leukemia (AML) will open enrollment this quarter, supported by a recently completed $27 million series B financing.
Researchers from the University College Cork have described the neuroprotective effect of TMP-269, a class-IIa-specific histone deacetylase (HDAC) inhibitor in preclinical models of PD. Pan-inhibitors of HDAC have proven effective in models of Parkinson’s disease (PD) by preventing dopaminergic degeneration.
Aconcagua Bio Inc. has divulged calcitonin receptor (CALCR; CT-R) and amylin receptor agonists reported to be useful for the treatment of pain, neurodegeneration, metabolic diseases, bone and cardiovascular disorders.
Shanghai Curegene Pharmaceutical Co. Ltd. has synthesized 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infections (COVID-19).
University of California has described tropane derivatives acting as 5-HT2 and muscarinic receptor ligands reported to be useful for the treatment of psychiatric disorders, depression, neurodegeneration, substance abuse and dependence, migraine, Alzheimer’s disease and Parkinson’s disease.
Aligos Therapeutics Inc. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment of hepatocellular carcinoma and hepatitis B.
Increland has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via a linker. They are described as potentially useful for the treatment of psoriasis.
One potentially serious complication of obstructive sleep apnea (OSA) is pulmonary hypertension (PH). Based on previous research that revealed involvement of perivascular immune and inflammatory responses in regulation of vascular remodeling and PH processing, researchers from Fudan University investigated the immunologic factors linked to OSA-induced PH.
One of the proteins required for centrosome clustering is kinesin family member C1 (KIFC1/HSET), and modulation of KIFC1 stability could reduce its activity in cancer cells.
RSS
